Please ensure Javascript is enabled for purposes of website accessibility

3 Biotech Stocks You Can Buy and Hold for the Next Decade

By Keith Speights – Aug 20, 2020 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Their approved treatment lineups and pipeline candidates should make them all winners through 2030 at least.

Risky. Speculative. Volatile. Take your pick of adjectives to describe investing in biotechs. Each of these descriptors can be applicable much of the time.

But not every biotech company fits that mold. Some are relatively stable, generating consistent and growing profits. Here are three biotech stocks that you can buy and hold for the next decade without losing any sleep.

2020 next to a ladder leading up to 2030

Image source: Getty Images.

1. Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX 0.33%) should have it made in the shade for at least the first half of this decade. The big biotech enjoys a monopoly in treating the underlying cause of cystic fibrosis (CF). Its nearest rival is at least several years away from even having a shot at winning regulatory approval for a CF candidate. And if a new contender does come to market, overcoming Vertex's head start won't be an easy task.

In the meantime, Vertex has secured key reimbursement deals that have opened up new markets for its CF drugs. Its latest entrant, Trikafta, has been a huge commercial success in the U.S., and appears to be headed for approval in Europe.

What about the second half of the decade? Vertex's CF franchise should still generate strong cash flow, and its pipeline also includes four non-CF programs currently in phase 2 testing that could win approval and be fueling further growth within a few years.

The company's two candidates targeting alpha-1 antitrypsin deficiency (AATD) rank at the top of the list. AATD, like CF, is a rare genetic disease caused by protein misfolding. And there are more patients in the U.S. alone with AATD than there are worldwide with CF. 

2. Bristol Myers Squibb

Should Bristol Myers Squibb (BMY -0.14%) be on a list of biotech stocks? Sure, the company is typically lumped into the big pharma category. However, given that most of its top-selling products are biologic drugs, it's arguably much more of a biotech than it is a traditional pharmaceutical company.

The company's product lineup ranks as one of the most impressive you'll find. Its acquisition of Celgene last year brought megablockbuster blood cancer drugs Revlimid and Pomalyst into its fold, along with solid tumor drug Abraxane. These added to the company's own big winners, including cancer immunotherapy Opdivo, arthritis drug Orencia, and blood thinner Eliquis.

Thanks to the Celgene deal, Bristol Myers Squibb also now has several new drugs with strong growth prospects. Zeposia is the most promising among them. The company recently launched the drug as a treatment for multiple sclerosis, and is evaluating it in late-stage studies as a potential treatment for Crohn's disease and ulcerative colitis.

Wall Street analysts project that Bristol Myers Squibb will deliver average annual earnings growth of more than 18% over the next five years. With its current lineup gaining momentum and a pipeline loaded with potential winners, its solid growth should be sustainable through 2030 and beyond.  

3. Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (REGN -0.73%) is probably best known for its tremendously successful eye-disease drug Eylea. While sales growth for the treatment has slowed, that could change if it gets approved for other indications.

Meanwhile, Regeneron has several other growth drivers. Dupixent, which the biotech co-markets with Sanofi, is now a blockbuster with sales that soared 70% year over year in the second quarter. The two companies have also partnered on the commercialization of two other fast-rising stars, cancer immunotherapy Libtayo and arthritis drug Kevzara.

The biotech's pipeline includes late-stage programs targeting additional indications for all of its top-selling products, including those already mentioned plus cholesterol drug Praluent. Regeneron also has promising new late-stage candidates including Ebola antibody therapy REGN-EB3 and osteoarthritis pain drug fasinumab.

Perhaps the most highly anticipated pipeline candidate for Regeneron, though, is its COVID-19 antibody therapy cocktail. Roche recently teamed up with the company to market that outside the U.S. if it wins regulatory approvals.

Keith Speights owns shares of Bristol Myers Squibb and Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Stock Quote
Bristol Myers Squibb
BMY
$79.03 (-0.14%) $0.11
Vertex Pharmaceuticals Stock Quote
Vertex Pharmaceuticals
VRTX
$316.33 (0.33%) $1.03
Regeneron Pharmaceuticals Stock Quote
Regeneron Pharmaceuticals
REGN
$736.08 (-0.73%) $-5.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.